Company Update (NYSE:MRK): Data for Merck’s Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation…

[Business Wire] – Merck , known as MSD outside the United States and Canada, today announced efficacy and safety data in previously untreated adults with HIV-1 infection for the company’s investigational once-daily formulation of ISENTRESS® , known as raltegravir 600 mg , from the ongoing Phase 3 pivotal trial called ONCEMRK. Read more on this. , valued at $recting to http://finance.ya, ended trading at $. Shares have traded today between $ per share and has traded between $ over the past 12 months. MRK shares are currently priced at x this year’s forecasted earnings, which makes them relatively inexpensive compared to the industry’s x earnings multiple. In a review of the consensus earnings estimate this quarter, 0 sell-side analysts are looking at $ per share, which would be $0.00 worse than the year-ago quarter and a $0.00 sequential decrease. The full-year EPS estimate is $ which would be a $0.00 worse than last year’s full-year earnings. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $0.00 . If realized, that would be a 0.00% decrease over the year-ago quarter. More recently, d MRK from to (/fi). Previously, d MRK from to . Investors should keep in mind is that the average price target is $, which is 0.00% below where the stock opened this morning. See more in (NYSE:MRK) Similar Articles: Market Update (NYSE:MRK): Merck Animal Health Receives FDA Approval of BRAVECTO® (fluralaner topical solution) for Cats and Dogs Company Update (NASDAQ:GILD): Gilead receives approval in Canada for EPCLUSA™ (sofosbuvir/velpatasvir), the first once-daily pan-genotypic (genotypes 1-6) single tablet regimen for the treatment of chronic hepatitis C Market Update: Merck & Co Inc (NYSE:MRK) – Merck’s Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study